中文
Press Release
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Dec 15, 2023
New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA

➞
Dec 14, 2023
Mabwell's Mailishu and Junmaikang Continuing to be Included in the National Medical Insurance Will Benefit More Patients

➞
Dec 07, 2023
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial

➞
Nov 28, 2023
Mabwell Partners with Innobic (Asia) Co., Ltd. to Market its products in Thailand

➞
Nov 16, 2023
Mabwell Announces the Appointment of Dr. Hai Wu as the President of R&D

➞
Oct 30, 2023
Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market

➞
Oct 25, 2023
Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell’s 9MW2821 at 2023 ESMO

➞
Oct 23, 2023
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

➞
Sep 27, 2023
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

➞
Sep 26, 2023
Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador

➞
1 2 3 4 Next